Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice

Background We previously reported that enhanced nuclear factor kappa B (NFκB) activity is responsible for resistance arteries dysfunction in type 2 diabetic mice. Methods In this study, we aimed to determine whether augmented NFκB activity also impairs conductance artery (thoracic aorta) function in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes/metabolism research and reviews 2015-01, Vol.31 (1), p.39-49
Hauptverfasser: Kassan, Modar, Choi, Soo-Kyoung, Galán, Maria, Trebak, Mohamed, Belmadani, Souad, Matrougui, Khalid
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 49
container_issue 1
container_start_page 39
container_title Diabetes/metabolism research and reviews
container_volume 31
creator Kassan, Modar
Choi, Soo-Kyoung
Galán, Maria
Trebak, Mohamed
Belmadani, Souad
Matrougui, Khalid
description Background We previously reported that enhanced nuclear factor kappa B (NFκB) activity is responsible for resistance arteries dysfunction in type 2 diabetic mice. Methods In this study, we aimed to determine whether augmented NFκB activity also impairs conductance artery (thoracic aorta) function in type 2 diabetic mice. We treated type 2 diabetic (db−/db−) and control (db−/db+) mice with two NFκB inhibitors (dehydroxymethylepoxyquinomicin, 6 mg/kg, twice a week and IKK‐NBD peptide, 500 µg/kg/day) for 4 weeks. Results As expected, the NFκB inhibition did not affect blood glucose level and body weight. Thoracic aorta vascular endothelium‐dependent relaxation (EDR), determined by the wire myograph, was impaired in diabetic mice compared with control and was significantly improved after NFκB inhibition. Interestingly, thoracic EDR was also rescued in db−/db−p50NFκB−/− and db−/db−PARP‐1−/− double knockout mice compared with db−/db− mice. Similarly, the acute in vitro down regulation of NFκB‐p65 using p65 shRNA lentiviral particles in arteries from db−/db− mice also improved thoracic aorta EDR. Western blot analysis showed that the p65NFκB phosphorylation, cleaved PARP‐1 and COX‐2 expression were increased in thoracic aorta from diabetic mice, which were restored after NFκB inhibition and in db−/db−p−50NFκB−/− and db−/db−PARP‐1−/− mice. Conclusions The present results indicate that in male type 2 diabetic mice, the augmented NFκB activity also impairs conductance artery function through PARP‐1 and COX‐2‐dependent mechanisms. Copyright © 2014 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/dmrr.2542
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4829069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3557980891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4812-22feb8bee122a2442aa9fd81947008e64d542f320d434a40b4d08f1d145440283</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi0EomXbA38AWeICh7T2xM7HBQkKbZHaIFVUSBywHGdC3SZ2sJPC_nuyyrICpJ48kp95NDMvIc85O-KMwXHTh3AEUsAjss8lsCSXGXu8qyXskWcx3jLGUpGJp2QPRCYhZ3KffKsm06EOtNVm9IHe6WHQ9B217sbWdrTeUdsPwd9jpMa7ZjKjdgapDiOGNW0nZxbI0XE9IAXaWF3jaA3trcED8qTVXcTD7bsi16cfPp-cJxefzj6evL1IjCg4JAAt1kWNyAE0CAFal21T8FLkjBWYiWZerk2BNSIVWrBaNKxoecOFFIJBka7Im8U7THWPjUE3Bt2pIdheh7Xy2qp_f5y9Ud_9vRIFlCwrZ8GrrSD4HxPGUfU2Guw67dBPUfH5YGlZ8hxm9OV_6K2fgpvXmykhJWcwH3pFXi-UCT7GgO1uGM7UJjW1SU1tUpvZF39PvyP_xDQDxwvw03a4ftik3l9eXW2VydJh44i_dh063KksT3OpvlRn6utllVfi_FRV6W95ZbEA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645510200</pqid></control><display><type>article</type><title>Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Kassan, Modar ; Choi, Soo-Kyoung ; Galán, Maria ; Trebak, Mohamed ; Belmadani, Souad ; Matrougui, Khalid</creator><creatorcontrib>Kassan, Modar ; Choi, Soo-Kyoung ; Galán, Maria ; Trebak, Mohamed ; Belmadani, Souad ; Matrougui, Khalid</creatorcontrib><description>Background We previously reported that enhanced nuclear factor kappa B (NFκB) activity is responsible for resistance arteries dysfunction in type 2 diabetic mice. Methods In this study, we aimed to determine whether augmented NFκB activity also impairs conductance artery (thoracic aorta) function in type 2 diabetic mice. We treated type 2 diabetic (db−/db−) and control (db−/db+) mice with two NFκB inhibitors (dehydroxymethylepoxyquinomicin, 6 mg/kg, twice a week and IKK‐NBD peptide, 500 µg/kg/day) for 4 weeks. Results As expected, the NFκB inhibition did not affect blood glucose level and body weight. Thoracic aorta vascular endothelium‐dependent relaxation (EDR), determined by the wire myograph, was impaired in diabetic mice compared with control and was significantly improved after NFκB inhibition. Interestingly, thoracic EDR was also rescued in db−/db−p50NFκB−/− and db−/db−PARP‐1−/− double knockout mice compared with db−/db− mice. Similarly, the acute in vitro down regulation of NFκB‐p65 using p65 shRNA lentiviral particles in arteries from db−/db− mice also improved thoracic aorta EDR. Western blot analysis showed that the p65NFκB phosphorylation, cleaved PARP‐1 and COX‐2 expression were increased in thoracic aorta from diabetic mice, which were restored after NFκB inhibition and in db−/db−p−50NFκB−/− and db−/db−PARP‐1−/− mice. Conclusions The present results indicate that in male type 2 diabetic mice, the augmented NFκB activity also impairs conductance artery function through PARP‐1 and COX‐2‐dependent mechanisms. Copyright © 2014 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 1520-7552</identifier><identifier>EISSN: 1520-7560</identifier><identifier>DOI: 10.1002/dmrr.2542</identifier><identifier>PMID: 24652705</identifier><identifier>CODEN: DMRRFM</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Animals ; Aorta, Thoracic - drug effects ; Aorta, Thoracic - physiopathology ; Arteries - drug effects ; Arteries - physiology ; Benzamides - pharmacology ; COX-2 ; Cyclohexanones - pharmacology ; Diabetes Mellitus, Experimental - physiopathology ; Diabetes Mellitus, Type 2 - physiopathology ; endothelial function ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiopathology ; Heart Conduction System - drug effects ; Heart Conduction System - physiology ; I-kappa B Proteins - pharmacology ; Male ; Mice ; Mice, Knockout ; NF-kappa B - antagonists &amp; inhibitors ; NFκB ; PARP-1 ; thoracic aorta ; type 2 diabetes ; Vasodilation - drug effects</subject><ispartof>Diabetes/metabolism research and reviews, 2015-01, Vol.31 (1), p.39-49</ispartof><rights>Copyright © 2014 John Wiley &amp; Sons, Ltd.</rights><rights>Copyright © 2015 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4812-22feb8bee122a2442aa9fd81947008e64d542f320d434a40b4d08f1d145440283</citedby><cites>FETCH-LOGICAL-c4812-22feb8bee122a2442aa9fd81947008e64d542f320d434a40b4d08f1d145440283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fdmrr.2542$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fdmrr.2542$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24652705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kassan, Modar</creatorcontrib><creatorcontrib>Choi, Soo-Kyoung</creatorcontrib><creatorcontrib>Galán, Maria</creatorcontrib><creatorcontrib>Trebak, Mohamed</creatorcontrib><creatorcontrib>Belmadani, Souad</creatorcontrib><creatorcontrib>Matrougui, Khalid</creatorcontrib><title>Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice</title><title>Diabetes/metabolism research and reviews</title><addtitle>Diabetes Metab Res Rev</addtitle><description>Background We previously reported that enhanced nuclear factor kappa B (NFκB) activity is responsible for resistance arteries dysfunction in type 2 diabetic mice. Methods In this study, we aimed to determine whether augmented NFκB activity also impairs conductance artery (thoracic aorta) function in type 2 diabetic mice. We treated type 2 diabetic (db−/db−) and control (db−/db+) mice with two NFκB inhibitors (dehydroxymethylepoxyquinomicin, 6 mg/kg, twice a week and IKK‐NBD peptide, 500 µg/kg/day) for 4 weeks. Results As expected, the NFκB inhibition did not affect blood glucose level and body weight. Thoracic aorta vascular endothelium‐dependent relaxation (EDR), determined by the wire myograph, was impaired in diabetic mice compared with control and was significantly improved after NFκB inhibition. Interestingly, thoracic EDR was also rescued in db−/db−p50NFκB−/− and db−/db−PARP‐1−/− double knockout mice compared with db−/db− mice. Similarly, the acute in vitro down regulation of NFκB‐p65 using p65 shRNA lentiviral particles in arteries from db−/db− mice also improved thoracic aorta EDR. Western blot analysis showed that the p65NFκB phosphorylation, cleaved PARP‐1 and COX‐2 expression were increased in thoracic aorta from diabetic mice, which were restored after NFκB inhibition and in db−/db−p−50NFκB−/− and db−/db−PARP‐1−/− mice. Conclusions The present results indicate that in male type 2 diabetic mice, the augmented NFκB activity also impairs conductance artery function through PARP‐1 and COX‐2‐dependent mechanisms. Copyright © 2014 John Wiley &amp; Sons, Ltd.</description><subject>Animals</subject><subject>Aorta, Thoracic - drug effects</subject><subject>Aorta, Thoracic - physiopathology</subject><subject>Arteries - drug effects</subject><subject>Arteries - physiology</subject><subject>Benzamides - pharmacology</subject><subject>COX-2</subject><subject>Cyclohexanones - pharmacology</subject><subject>Diabetes Mellitus, Experimental - physiopathology</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>endothelial function</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Heart Conduction System - drug effects</subject><subject>Heart Conduction System - physiology</subject><subject>I-kappa B Proteins - pharmacology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>NF-kappa B - antagonists &amp; inhibitors</subject><subject>NFκB</subject><subject>PARP-1</subject><subject>thoracic aorta</subject><subject>type 2 diabetes</subject><subject>Vasodilation - drug effects</subject><issn>1520-7552</issn><issn>1520-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1v1DAQhi0EomXbA38AWeICh7T2xM7HBQkKbZHaIFVUSBywHGdC3SZ2sJPC_nuyyrICpJ48kp95NDMvIc85O-KMwXHTh3AEUsAjss8lsCSXGXu8qyXskWcx3jLGUpGJp2QPRCYhZ3KffKsm06EOtNVm9IHe6WHQ9B217sbWdrTeUdsPwd9jpMa7ZjKjdgapDiOGNW0nZxbI0XE9IAXaWF3jaA3trcED8qTVXcTD7bsi16cfPp-cJxefzj6evL1IjCg4JAAt1kWNyAE0CAFal21T8FLkjBWYiWZerk2BNSIVWrBaNKxoecOFFIJBka7Im8U7THWPjUE3Bt2pIdheh7Xy2qp_f5y9Ud_9vRIFlCwrZ8GrrSD4HxPGUfU2Guw67dBPUfH5YGlZ8hxm9OV_6K2fgpvXmykhJWcwH3pFXi-UCT7GgO1uGM7UJjW1SU1tUpvZF39PvyP_xDQDxwvw03a4ftik3l9eXW2VydJh44i_dh063KksT3OpvlRn6utllVfi_FRV6W95ZbEA</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Kassan, Modar</creator><creator>Choi, Soo-Kyoung</creator><creator>Galán, Maria</creator><creator>Trebak, Mohamed</creator><creator>Belmadani, Souad</creator><creator>Matrougui, Khalid</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201501</creationdate><title>Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice</title><author>Kassan, Modar ; Choi, Soo-Kyoung ; Galán, Maria ; Trebak, Mohamed ; Belmadani, Souad ; Matrougui, Khalid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4812-22feb8bee122a2442aa9fd81947008e64d542f320d434a40b4d08f1d145440283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Aorta, Thoracic - drug effects</topic><topic>Aorta, Thoracic - physiopathology</topic><topic>Arteries - drug effects</topic><topic>Arteries - physiology</topic><topic>Benzamides - pharmacology</topic><topic>COX-2</topic><topic>Cyclohexanones - pharmacology</topic><topic>Diabetes Mellitus, Experimental - physiopathology</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>endothelial function</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Heart Conduction System - drug effects</topic><topic>Heart Conduction System - physiology</topic><topic>I-kappa B Proteins - pharmacology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>NF-kappa B - antagonists &amp; inhibitors</topic><topic>NFκB</topic><topic>PARP-1</topic><topic>thoracic aorta</topic><topic>type 2 diabetes</topic><topic>Vasodilation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kassan, Modar</creatorcontrib><creatorcontrib>Choi, Soo-Kyoung</creatorcontrib><creatorcontrib>Galán, Maria</creatorcontrib><creatorcontrib>Trebak, Mohamed</creatorcontrib><creatorcontrib>Belmadani, Souad</creatorcontrib><creatorcontrib>Matrougui, Khalid</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes/metabolism research and reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kassan, Modar</au><au>Choi, Soo-Kyoung</au><au>Galán, Maria</au><au>Trebak, Mohamed</au><au>Belmadani, Souad</au><au>Matrougui, Khalid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice</atitle><jtitle>Diabetes/metabolism research and reviews</jtitle><addtitle>Diabetes Metab Res Rev</addtitle><date>2015-01</date><risdate>2015</risdate><volume>31</volume><issue>1</issue><spage>39</spage><epage>49</epage><pages>39-49</pages><issn>1520-7552</issn><eissn>1520-7560</eissn><coden>DMRRFM</coden><abstract>Background We previously reported that enhanced nuclear factor kappa B (NFκB) activity is responsible for resistance arteries dysfunction in type 2 diabetic mice. Methods In this study, we aimed to determine whether augmented NFκB activity also impairs conductance artery (thoracic aorta) function in type 2 diabetic mice. We treated type 2 diabetic (db−/db−) and control (db−/db+) mice with two NFκB inhibitors (dehydroxymethylepoxyquinomicin, 6 mg/kg, twice a week and IKK‐NBD peptide, 500 µg/kg/day) for 4 weeks. Results As expected, the NFκB inhibition did not affect blood glucose level and body weight. Thoracic aorta vascular endothelium‐dependent relaxation (EDR), determined by the wire myograph, was impaired in diabetic mice compared with control and was significantly improved after NFκB inhibition. Interestingly, thoracic EDR was also rescued in db−/db−p50NFκB−/− and db−/db−PARP‐1−/− double knockout mice compared with db−/db− mice. Similarly, the acute in vitro down regulation of NFκB‐p65 using p65 shRNA lentiviral particles in arteries from db−/db− mice also improved thoracic aorta EDR. Western blot analysis showed that the p65NFκB phosphorylation, cleaved PARP‐1 and COX‐2 expression were increased in thoracic aorta from diabetic mice, which were restored after NFκB inhibition and in db−/db−p−50NFκB−/− and db−/db−PARP‐1−/− mice. Conclusions The present results indicate that in male type 2 diabetic mice, the augmented NFκB activity also impairs conductance artery function through PARP‐1 and COX‐2‐dependent mechanisms. Copyright © 2014 John Wiley &amp; Sons, Ltd.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>24652705</pmid><doi>10.1002/dmrr.2542</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1520-7552
ispartof Diabetes/metabolism research and reviews, 2015-01, Vol.31 (1), p.39-49
issn 1520-7552
1520-7560
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4829069
source MEDLINE; Access via Wiley Online Library
subjects Animals
Aorta, Thoracic - drug effects
Aorta, Thoracic - physiopathology
Arteries - drug effects
Arteries - physiology
Benzamides - pharmacology
COX-2
Cyclohexanones - pharmacology
Diabetes Mellitus, Experimental - physiopathology
Diabetes Mellitus, Type 2 - physiopathology
endothelial function
Endothelium, Vascular - drug effects
Endothelium, Vascular - physiopathology
Heart Conduction System - drug effects
Heart Conduction System - physiology
I-kappa B Proteins - pharmacology
Male
Mice
Mice, Knockout
NF-kappa B - antagonists & inhibitors
NFκB
PARP-1
thoracic aorta
type 2 diabetes
Vasodilation - drug effects
title Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T02%3A41%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nuclear%20factor%20kappa%20B%20inhibition%20improves%20conductance%20artery%20function%20in%20type%202%20diabetic%20mice&rft.jtitle=Diabetes/metabolism%20research%20and%20reviews&rft.au=Kassan,%20Modar&rft.date=2015-01&rft.volume=31&rft.issue=1&rft.spage=39&rft.epage=49&rft.pages=39-49&rft.issn=1520-7552&rft.eissn=1520-7560&rft.coden=DMRRFM&rft_id=info:doi/10.1002/dmrr.2542&rft_dat=%3Cproquest_pubme%3E3557980891%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645510200&rft_id=info:pmid/24652705&rfr_iscdi=true